PUBLISHER: Grand View Research | PRODUCT CODE: 1888673
PUBLISHER: Grand View Research | PRODUCT CODE: 1888673
The global acute respiratory disease diagnostics market size was estimated at USD 5.49 billion in 2024 and is projected to reach USD 10.71 billion by 2033, growing at a CAGR of 7.01% from 2025 to 2033. Some of the major factors driving the market are rising disease burden of respiratory conditions, advancements in diagnostic technologies, and increasing demand for early detection & decentralized testing.
According to the Institute for Health Metrics and Evaluation (IHME) in April 2023, chronic respiratory diseases (CRDs) are the third leading cause of death globally. Furthermore, the market growth is driven by the ageing demographic shift, increased healthcare infrastructure & investment in developing markets, government initiatives, public health programs & funding. The rise in the proportion of older people globally has led to an increase in cases of respiratory disorders, as older age is often associated with decreased lung capacity and decreased immune functioning. This demographic shift introduces significant risk for the development of chronic and acute infections with co-morbidities, including pneumonia, chronic obstructive pulmonary disease (COPD), and influenza. As a result, there is an increasing demand for rapid and accurate diagnostic tools for early detection, timely intervention, and improved clinical outcomes among the aging demographic.
Simultaneously, the healthcare infrastructure in emerging economies is rapidly expanding, providing a solid base for the adoption of new diagnostic techniques. Countries in the Asia-Pacific, Latin America, and Middle East regions are seeing significant investments in the modernization of healthcare, laboratory automation, and the development of innovative devices. Governments and private healthcare providers are collaborating to enhance diagnostic capacity through public-private partnerships, the establishment of specialized respiratory testing centers, and the implementation of point-of-care testing. These efforts will lead to increased access to diagnostic services, shorter turnaround times, and enhanced disease management in both urban and rural areas.
In addition, government programs and international public health initiatives play a crucial role in supporting the global diagnostic ecosystem. Existing efforts by the WHO, the Global Fund, and the Ministries of Health of various countries to enhance surveillance of respiratory diseases, fund research, and provide equitable access to critical diagnostic supplies indicate that the global diagnostic community is working collaboratively to strengthen diagnostic capabilities worldwide and improve public health. Changes in reimbursement environments, public awareness campaigns, global strategic funding for innovations, and collaborative research efforts are reshaping global adherence to molecular and digital diagnostics. Overall, these aims aim to provide an ecosystem and ultimately improve public health by reducing the burden of acute respiratory disease through early, accurate, and accessible diagnostics.
Global Acute Respiratory Disease Diagnostics Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global acute respiratory disease diagnostics market based on test, pathogen, end-use, and region: